Imoto Jun-Ichi, Konishi Eiji
Department of Health Sciences, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan.
Vaccine. 2007 Jan 22;25(6):1076-84. doi: 10.1016/j.vaccine.2006.09.059. Epub 2006 Oct 2.
We previously developed a dengue tetravalent DNA vaccine that can induce neutralizing antibodies against four dengue viruses in mice. Here, we demonstrated that immunogenicity of our tetravalent vaccine is synergistically increased in mice by co-immunization with dengue type 2 virus (DENV2) subviral extracellular particles (D2EPs) or inactivated Japanese encephalitis vaccine (JEVAX). A single immunization with a mixture of 100 microg of the tetravalent vaccine and 150 ng of D2EPs or a 1/10 dose of JEVAX induced moderate levels of neutralizing antibodies in a 90% plaque reduction assay. Immunized mice were protected from "artificial" viremia created by intravenous injection with DENV2.
我们之前研发了一种登革热四价DNA疫苗，该疫苗可在小鼠体内诱导产生针对四种登革热病毒的中和抗体。在此，我们证明，通过与2型登革热病毒（DENV2）亚病毒细胞外颗粒（D2EPs）或灭活的日本脑炎疫苗（JEVAX）共同免疫，我们的四价疫苗在小鼠体内的免疫原性会协同增强。在90%蚀斑减少试验中，用100微克四价疫苗与150纳克D2EPs的混合物或1/10剂量的JEVAX进行单次免疫，可诱导产生中等水平的中和抗体。免疫后的小鼠可免受静脉注射DENV2所产生的“人工”病毒血症的影响。
